Phio Pharma gets SMC OK to escalate PH-762 dose in Phase 1b; no dose-limiting toxicities

Phio Pharmaceuticals Corp.

Safety Monitoring Committee recommended dose escalation to next concentration after initial cohort.
No dose-limiting toxicities or clinically relevant treatment-emergent adverse events observed.
PH-762 intratumoral injections were well tolerated in the first dose cohort.
Phase 1b trial (NCT06014086) targets cutaneous squamous cell carcinoma, melanoma, Merkel cell carcinoma.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.